From: Nucleated red blood cells, critical illness survivors and postdischarge outcomes: a cohort study
 | 0/μl | 1-100/μl | 101-200/μl | >200/μl | P value (chi-square test) |
---|---|---|---|---|---|
N | 1867 | 487 | 101 | 114 | Â |
Male gender | 1025 (55) | 248 (51) | 60 (59) | 57 (50) | 0.22 |
Nonwhite race | 380 (20) | 109 (22) | 20 (20) | 27 (24) | 0.66 |
Age (years) | 60.1 ± 18.5 | 62.7 ± 16.4 | 63.2 ± 15.4 | 61.4 ± 17.4 | 0.014* |
Surgical patient type | 785 (42) | 253 (52) | 55 (54) | 54 (47) | <0.001 |
Deyo–Charlson Index |  |  |  |  | <0.001 |
 0 | 444 (24) | 63 (13) | 9 (9) | 17 (15) |  |
 1–2 | 473 (25) | 111 (23) | 21 (21) | 23 (20) |  |
 3–6 | 394 (21) | 113 (23) | 30 (30) | 29 (25) |  |
 ≥7 | 556 (30) | 200 (41) | 41 (41) | 45 (40) |  |
Sepsis | 118 (6) | 77 (16) | 22 (22) | 24 (21) | <0.001 |
Pneumonia | 293 (16) | 125 (26) | 31 (31) | 38 (33) | <0.001 |
Noncardiac acute respiratory failure | 98 (5) | 45 (9) | 13 (13) | 13 (11) | <0.001 |
Acute organ failure | Â | Â | Â | Â | <0.001 |
 0 | 721 (39) | 94 (19) | 10 (10) | 18 (16) |  |
 1 | 663 (36) | 169 (35) | 37 (37) | 26 (23) |  |
 2 | 337 (18) | 118 (24) | 25 (25) | 28 (25) |  |
 ≥3 | 146 (8) | 106 (22) | 29 (29) | 42 (37) |  |
Leukemia or myelodysplastic syndrome | 131 (7) | 55 (11) | 19 (19) | 24 (21) | <0.001 |
Hematocrit | 35.5 ± 6.6 | 31.2 ± 6.6 | 29.2 ± 7.4 | 28.8 ± 7.0 | <0.001 |
Red cell distribution width | 13.9 (13.1–15.1) | 15.3 (14.2–17.1) | 16.3 (15.1–18.0) | 17.1 (15.5–19.3) |  |
Chronic kidney disease | 510 (27) | 197 (40) | 39 (39) | 54 (47) | <0.001 |
Transfusions | 0 (0–0) | 0 (0–1) | 1 (0–3) | 0 (0–2) | <0.001†|
Acute Organ Failure score | 9.5 ± 4.4 | 10.9 ± 4.9 | 11.9 ± 5.1 | 12.0 ± 5.9 | <0.001* |
NRBCs | 0 (0–0) | 40 (20–60) | 140 (120–170) | 375 (270–690) | <0.001†|
Postdischarge mortality rate (%) | Â | Â | Â | Â | Â |
 30-day | 58 (3.1) | 34 (7.0) | 12 (11.9) | 17 (14.9) | <0.001 |
 90-day | 111 (6.0) | 57 (11.7) | 16 (15.8) | 25 (21.9) | <0.001 |